Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14088106 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL112331 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL7999610 | 0.87 | KDM4E (0.63) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL5599294 | 0.87 | KDM4E (0.63) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL2298043 | 0.87 | KDM4E (0.63) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL7999598 | 0.87 | KDM4E (0.63) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL23870628 | 0.85 | KDM4E (0.61) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL6815850 | 0.85 | KDM4E (0.61) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL7758252 | 0.85 | KDM4E (0.61) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL4984084 | 0.84 | SMN1; SMN2 (0.43) | SMN1; SMN2KDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 557 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626414-A1 | SYNERGISTIC COMBINATIONS OF REGULATED NECROSIS INHIBITORS WITH N-ACETYLCYSTEINE | Seabelife (FR) | 2025-10-08 | — | — | EP | claimed |
| US-12435294-B2 | Prevention of the oxidation of perfumery raw materials and food raw materials | FIRMENICH SA (CH) | 2025-10-07 | — | — | US | claimed |
| US-20250255843-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | Nature's Fusions, LLC | 2025-08-14 | — | — | US | claimed |
| EP-4561372-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | Nature's Fusions, LLC (US) | 2025-06-04 | — | — | EP | claimed |
| WO-2025111296-A1 | ELECTROLYTE COMPOSITIONS AND ELECTROCHEMICAL DEVICES USING THE SAME | II-VI DELAWARE, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250118803-A1 | NONAQUEOUS ELECTROLYTE FOR NONAQUEOUS-ELECTROLYTE CELL, AND NONAQUEOUS-ELECTROLYTE CELL | PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) | 2025-04-10 | — | — | US | claimed |
| CN-119528644-A | Plant underground propagule excitant | 中国科学院植物研究所 | 2025-02-28 | — | — | CN | claimed |
| EP-4475255-A1 | NONAQUEOUS ELECTROLYTE FOR NONAQUEOUS-ELECTROLYTE CELL, AND NONAQUEOUS-ELECTROLYTE CELL | Panasonic Intellectual Property Management Co., Ltd. (JP) | 2024-12-11 | — | — | EP | claimed |
| CN-119097576-A | Preventing oxidation of flavor raw material and food raw material | 弗门尼舍有限公司 | 2024-12-10 | — | — | CN | claimed |
| CN-119039370-A | Saccharide derivative for promoting glycosylation of human peripheral blood mononuclear cells and application thereof | 华谱生物科技研究(东莞)有限公司 | 2024-11-29 | — | — | CN | claimed |
| WO-2010127193-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | claimed |
| US-RE41339-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2010-05-18 | — | — | US | claimed |
| EP-0784471-B1 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | HIV DIAGNOSTICS INC (US) | 2005-06-08 | — | — | EP | claimed |
| US-20030229141-A1 | N-acetyl cysteine and its topical use | YU RUEY J (US) | 2003-12-11 | — | — | US | claimed |
| US-6514955-B1 | An agent in an amount effective to cause blood glutathione levels to increase, antioxidants at a dose higher than the recommended daily minimum requirement; and nuclear factor kappa B (NFKB) induction inhibitor | HIV DIAGNOSTICS, INC. | 2003-02-04 | — | — | US | claimed |
| US-5846961-A | Multi-faceted method to repress reproduction of latent viruses in humans and animals | HIV DIAGNOSTICS, INC. (US) | 1998-12-08 | — | — | US | claimed |
| EP-0784471-A4 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | DYKE KNOX VAN (US) | 1997-11-19 | — | — | EP | claimed |
| US-5686436-A | SUPPRESSING HUMAN IMMUNODEFICIENCY VIRUS, FELINE IMMUNODEFICIENCY VIRUS, FELINE LEUKEMIA VIRUS | HIV DIAGNOSTICS, INC. (US) | 1997-11-11 | — | — | US | claimed |
| EP-0784471-A2 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | Van Dyke, Knox (US) | 1997-07-23 | — | — | EP | claimed |
| WO-1996010402-A1 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | DYKE KNOX VAN (US) | 1996-04-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255843-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | AHCY, MGMT, CBS | SMN1; SMN2 4541/4885KDM4E 2170/4885MAPT 2515/4885 |
| US-12435294-B2 | Prevention of the oxidation of perfumery raw materials and food raw materials | CUTA, MPO, GPX4 | SMN1; SMN2 2584/4885KDM4E 4695/4885MAPT 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.